| Old Articles: <Older 8621-8630 Newer> |
|---|
 |
Chemistry World
July 1, 2013
Laura Howes |
Aspen in $1 billion deal with Merck The deal involves 11 of Merck's drug brands and an active pharmaceutical ingredient business in the Netherlands.   |
CRM
July 2013
Leonard Klie |
Drug Makers Are in the Midst of a Digital Revolution Pharmaceutical firms are sharpening their focus on multichannel marketing and analytics. |
Chemistry World
June 28, 2013
Phillip Broadwith |
Data-sharing partnership for drug discovery AstraZeneca and Roche are pooling their data on compound properties to boost their chances of success in early stage drug development. |
Chemistry World
June 27, 2013
Phillip Broadwith |
Ups and downs for erectile dysfunction drugs Spedra (avanafil) aims to compete for a share of the lucrative ED market, trading on the fact that it is much faster-acting than other available drugs. |
CIO
June 25, 2013
Maryfran Johnson |
The Dangers of Disconnected Data CIOs in the food and pharma industries confront unique challenges in untangling complex supply chains to ensure product safety and availability. |
Chemistry World
June 26, 2013
Emma Stoye |
UN report warns of global rise in legal highs The latest World Drug Report from the United Nations Office on Drugs and Crime says governments around the world are struggling to cope with a growing number of legal party drugs. |
Chemistry World
June 25, 2013
Emma Stoye |
NHS to offer breast cancer prevention drugs New guidelines for the UK National Health Service suggest that women at high risk of breast cancer should be offered a five-year course of tamoxifen or raloxifene to prevent the disease developing. |
Pharmaceutical Executive
June 1, 2013
Clark Herman |
Adherence's New Players: Fresh Support from the Sidelines New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. |
Pharmaceutical Executive
June 1, 2013 |
Unlocking the Key to Public Funding in Brazil Brazil, the world's sixth largest pharmaceutical market, has joined the ranks of countries requiring a formal and transparent assessment of a drug's cost-effectiveness, budgetary impact, and medical need to gain access to the public sector. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
Regeneron: New York State of Mind Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo. |
| <Older 8621-8630 Newer> Return to current articles. |
